Research programme: multiple sclerosis therapy - Salus Therapeutics

Drug Profile

Research programme: multiple sclerosis therapy - Salus Therapeutics

Alternative Names: Multiple sclerosis therapy research programme - Salus Therapeutics

Latest Information Update: 09 Mar 2015

Price : $50

At a glance

  • Originator Genta
  • Developer Genta (CEASED)
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 30 Aug 2001 Preclinical development for Multiple sclerosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top